- Details
- Alicia Morgans is joined by Noel Clarke to discuss his work in clinically relevant biomarkers in castration-resistant prostate cancer (CRPC). Professor Clarke emphasizes the importance of using the available data that you have, keeping the patient at the very center of your thought processes, and regarding the patient as a whole rather than someone with prostate cancer. He highlights factors such...
|
- Details
- Alicia Morgans and Cora Sternberg discuss the MAGNITUDE phase 3 trial which was pragmatically designed to test the benefit of the combination of niraparib + abiraterone acetate/prednisone for metastatic castration-resistant prostate cancer (mCRPC) in patients prospectively identified with and without alterations in genes associated with HRR using both tissue and blood-based approaches. Dr. Sternbe...
|
- Details
- In this conversation with Alicia Morgans, Simpa Salami discusses transcriptomic heterogeneity in multifocal prostate cancer and factors predisposing certain prostate cancer-focused to metastasis. Simpa Salami is a Prostate Cancer Foundation (PCF) Young Investigator Award recipient. Highlighting key takeaways from two research studies, Dr. Salami also shares how the PCF funding has supported this r...
|
- Details
- In this conversation with Charles Ryan, Simpa Salami highlights a new urine-based test for detecting aggressive prostate cancer, which promises improvement upon current biomarker tests. It's been estimated that prostate cancer often occurs in multiple areas of the prostate in about 60% to 80% of patients. Prostate biopsy is the strategy for detecting aggressive prostate cancer based upon elevated...
|
- Details
- In this conversation, Alicia Morgans and Alan Bryce highlighted the TRITON3 study. TRITON3 is a Phase 3, multicenter, open-label, randomized trial of Rubraca in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC). The study enrolled 405 patients with a mutation in BRCA or ATM who were randomized to Rubraca or the control group, which consisted of the physician’...
|
- Details
- In this discussion, Michael Morris and Alicia Morgans discuss a post hoc analysis of the VISION Trial aimed at assessing earlier maturing time-to-event endpoints. Earlier time-to-event endpoints than overall survival (OS) will allow more timely regulatory approval and overall accelerated drug development. Morris and colleagues aimed to estimate correlations between time-to-event endpoints such as...
|
- Details
- Samuel Denmeade, Co-Director of the Johns Hopkins Prostate Cancer Program joins Alicia Morgans in a discussion on Bipolar Androgen Therapy (BAT) for prostate cancer. ADT slows prostate cancer’s progress by shutting off testosterone. Eventually, cancer adapts to this new environment and PSA levels start to rise. The concept of BAT is for men whose prostate cancer has become resistant to standard ho...
|
- Details
- Martin Sjöström joins Alicia Morgans in a conversation on the 2021 Michael and Patricia Berns-PCF Young Investigator Award research studying epigenetic modifications that drive lineage plasticity and treatment resistance in prostate cancer. This research aims to develop a new liquid biopsy biomarker platform for men with prostate cancer. Sjöström refers to the ability to take a blood sample and pr...
|
- Details
- Alicia Morgans and Emmanuel Antonarakis discuss an ongoing biomarker analysis aimed at identifying a molecular signature predictive of response in the COMBAT study. The COMBAT study is a multi-center, single-arm, open label Phase 2 study in asymptomatic patients with mCRPC who had soft tissue metastases amenable to biopsy, and who progressed on at least one prior novel AR-targeted therapy (and up...
|
- Details
- Christopher Wallis and Zachary Klaassen discuss the Annals of Oncology article titled “Cabazitaxel versus abiraterone or enzalutamide in poor prognosis metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2 trial.” The goal of this publication was to determine the optimal treatment for poor prognosis metastatic castration-resistant prostate cancer (mCRPC) p...
|
